

## Supplementary File 1

### Participants Characteristics in the Voting Sessions

Table S1 Participants Characteristics

<b>Participant number</b>	<b>Title</b>	<b>Health Authority</b>
1	Director Dubai Health Insurance Fund	EHES
2	Manager of Drugs & Medical Products	DOH
3	Clinical Pharmacist - Oncology - Tawam	SEHA
4	Senior Specialist	ADEO
5	Consultant Rheumatology & Head of SEHA Committee	SEHA
6	Director Dubai Health Insurance Fund	EHES
7	Clinical Pharmacist - MOH	EHS
8	President of Emirates Health Economics Society	EHES
9	Advisor Undersecretary Office - DOH	DOH
10	DOH - Payer sector - Authorization	DOH
11	DOH - Payer sector - Authorization	DOH
12	DOH - Payer sector - Authorization	DOH
13	Clinical Pharmacist & Pharmacy Head at SKMC	SEHA
14	Clinical Pharmacist	SEHA
15	Clinical Pharmacist	SEHA
16	Clinical Pharmacist	SEHA
17	Clinical Pharmacist & Pharmacy Head at SSMC	SSMC
18	Clinical Pharmacist	SSMC
19	Clinical Pharmacist	SSMC
20	Clinical Pharmacist - Tawam	SEHA
21	Clinical Pharmacist - Tawam	SEHA
22	Clinical Pharmacist - Tawam	SEHA
23	Section Head Technology Assessment and Innovation	DOH

EHES: Emirates Health Economics Society, DOH: Department of Health, SEHA: Abu Dhabi Health Services Company, ADEO: Abu Dhabi Executive Office, EHS: Emirates Health Services, SSMC: Sheikh Shakhbout Medical City

## CET Application (Example)

The following is an example for calculating the CET:

For treating disease X, two interventions, A and B, were evaluated, with intervention A achieving a QALY gain of 1.5 and intervention B a QALY gain of 2.0. The average lifespan of individuals with the disease is 75 years, in comparison to 85 years for those without the condition. Furthermore, disease X is categorized as a rare disease by regulatory authorities such as the EMA or FDA.

Based on the provided information, the CET is calculated as follows:

- 1- Calculate the proportional/relative shortfall

$$\text{Proportional/ Relative Shortfall} = \frac{\text{Disease-related QALY loss (AS)}}{\text{Remaining QALY expectation in the absence of the disease}}$$

$$\text{Proportional/RelativeShortfall} = \frac{(85 - 75)}{85} = \mathbf{0.1176} \text{ --- > (1)}$$

- 2- Calculate the IRQG

$$\text{IRQG} = \frac{\text{QALY}_{\text{new technology}} - \text{QALY}_{\text{comparator}}}{\text{QALY}_{\text{new technology}}}$$

$$\text{IRQG} = \frac{2 - 1.5}{2} = \mathbf{0.25} \text{ --- > (2)}$$

- 3- Assess the rarity of the disease

According to the provided information, Disease X is considered a rare disease according to the FDA and EMA.

Therefore

$$\text{is\_Rare} = \mathbf{1} \text{ --- > (3)}$$

Based on (1), (2), and (3), the multiplier for calculating the CET =

$$\text{Multiplier} = (\text{Relative Shortfall} + 1) \times (\text{IRQG} + 1) \times (\text{is\_rare} \times 2 + 1)$$

$$\text{Multiplier} = (0.12 + 1) \times (0.25 + 1) \times (1 \times 2 + 1) = 4.19$$

Therefore, the CET is calculated as follows:

$$\text{CET (localcurrency)} = 0.75 \times \text{Multiplier} \times \text{GDP/Capita}$$

$$\text{CET (localcurrency)} = 0.75 \times 4.19 \times 194,425 = 611,152 \text{ AED}$$